<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776488</url>
  </required_header>
  <id_info>
    <org_study_id>MT01</org_study_id>
    <nct_id>NCT02776488</nct_id>
  </id_info>
  <brief_title>Metabolic Therapy for Traumatic Brain Injury</brief_title>
  <acronym>MT-TBI</acronym>
  <official_title>Metabolic Therapy for Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as
      indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed safety
      analysis of glucose and sodium lactate infusions in humans and have demonstrated proof of
      concept that these fuels alter brain metabolism. We will conduct a multicenter, adaptive
      design-based, proof of concept unblinded phase 2 study of up to 3 candidate supplemental
      fuels infused over 3 hours in patients with severe traumatic brain injury undergoing standard
      of care multimodality monitoring with cerebral microdialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic crisis is a state of energy insufficiency due to impaired mitochondrial function as
      indicated by cerebral microdialysis lactate/pyruvate ratio (LPR). We have performed safety
      analysis of glucose and sodium lactate infusions in humans and have demonstrated proof of
      concept that these fuels alter brain metabolism. Animal TBI studies have demonstrated proof
      of concept for all three candidate fuels. We will conduct a multicenter, adaptive
      design-based, proof of concept unblinded phase 2 study of up to 3 candidate supplemental
      fuels infused over 3 hours in patients with severe TBI undergoing standard of care
      multimodality monitoring with cerebral microdialysis. The three candidate fuels are be
      glucose, sodium lactate, and beta-hydroxybutyrate, with doses to be established in animal
      models. Infusions will be guided by point of care testing to achieve the ideal blood
      concentration during the infusion during the infusion.

      This is a 5-year safety study using a parallel intervention model with 4 arms, open-label,
      non-randomized.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of the cerebral microdialysis lactate/pyruvate ratio (LPR)</measure>
    <time_frame>30 days</time_frame>
    <description>LPR obtained from measures of fluid through a brain catheter is a marker of metabolic crisis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
    <description>Treatment effect at least noninferior to available comparators, using all-cause mortality within each timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frontal lobe atrophy</measure>
    <time_frame>6 months post injury</time_frame>
    <description>Frontal lobe atrophy obtained from brain imaging using magnetic resonance imaging at follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale - Extended</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Functional outcome assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayo-Portland Adaptability Inventory-4</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Physical, cognitive, emotional, behavioral, and social assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Assessment of attention and executive ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-traumatic Amnesia Questionnaire</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Assessment of orientation to person, place and time, and retention of new information</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hooper Visual Organization Test</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Assessment of visuoperception</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of glucose as supplemental fuel (dosage form = solute, dosage to be determined, frequency = 1x, duration = 3hr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of sodium lactate as supplemental fuel (dosage form = solute, dosage TBD, frequency = 1x, duration = 3hr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta-hydroxybutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of beta-hydroxybutyrate as supplemental fuel (dosage form = solute, dosage TBD, frequency = 1x, duration = 3hr)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Less than one fifth of one ounce of glucose mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of standard brain chemistry analyses.</description>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactate</intervention_name>
    <description>Less than two thirds of an ounce of lactate mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of the standard brain chemistry analyses.</description>
    <arm_group_label>Lactate</arm_group_label>
    <other_name>Sodium lactate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-hydroxybutyrate</intervention_name>
    <description>Less than one tenth of one ounce of hydroxybutyrate mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of the standard brain chemistry analyses.</description>
    <arm_group_label>Beta-hydroxybutyrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients seen in the Medical Center Emergency Department

          -  Adult patients transferred to the Neurocritical Intensive Care Unit with a physician's
             diagnosis of brain injury.

        Exclusion Criteria:

          -  Pregnancy at time of injury

          -  History of diabetes mellitus

          -  History of hemodynamic instability

          -  Known terminal illness which alters brain functioning

          -  Diagnosed AIDS progressed to AIDS dementia

          -  Known history of chronic severe neurological disturbance

          -  Severe retardation

          -  Previous severe diminished mental capacity

          -  No command of either English or Spanish

          -  Arrest for a felony
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Vespa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Los Angeles, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney Real, BSN RN</last_name>
    <phone>310-267-7433</phone>
    <email>creal@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David L McArthur, PhD MPH</last_name>
    <phone>310-825-0688</phone>
    <email>dmca@ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Cohen, MHA</last_name>
      <phone>310-794-1801</phone>
      <email>steven.cohen@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glenn TC, Martin NA, Horning MA, McArthur DL, Hovda DA, Vespa P, Brooks GA. Lactate: brain fuel in human traumatic brain injury: a comparison with normal healthy control subjects. J Neurotrauma. 2015 Jun 1;32(11):820-32. doi: 10.1089/neu.2014.3483. Epub 2015 Mar 31.</citation>
    <PMID>25594628</PMID>
  </reference>
  <reference>
    <citation>Glenn TC, Martin NA, McArthur DL, Hovda DA, Vespa P, Johnson ML, Horning MA, Brooks GA. Endogenous Nutritive Support after Traumatic Brain Injury: Peripheral Lactate Production for Glucose Supply via Gluconeogenesis. J Neurotrauma. 2015 Jun 1;32(11):811-9. doi: 10.1089/neu.2014.3482. Epub 2015 Mar 11.</citation>
    <PMID>25279664</PMID>
  </reference>
  <reference>
    <citation>Vespa P, McArthur DL, Stein N, Huang SC, Shao W, Filippou M, Etchepare M, Glenn T, Hovda DA. Tight glycemic control increases metabolic distress in traumatic brain injury: a randomized controlled within-subjects trial. Crit Care Med. 2012 Jun;40(6):1923-9. doi: 10.1097/CCM.0b013e31824e0fcc.</citation>
    <PMID>22610193</PMID>
  </reference>
  <reference>
    <citation>Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC, McArthur DL, Hovda DA. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab. 2005 Jun;25(6):763-74.</citation>
    <PMID>15716852</PMID>
  </reference>
  <reference>
    <citation>Vespa P, Tubi M, Claassen J, Buitrago-Blanco M, McArthur D, Velazquez AG, Tu B, Prins M, Nuwer M. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol. 2016 Apr;79(4):579-90. doi: 10.1002/ana.24606. Epub 2016 Feb 28.</citation>
    <PMID>26814699</PMID>
  </reference>
  <reference>
    <citation>Xu Y, McArthur DL, Alger JR, Etchepare M, Hovda DA, Glenn TC, Huang S, Dinov I, Vespa PM. Early nonischemic oxidative metabolic dysfunction leads to chronic brain atrophy in traumatic brain injury. J Cereb Blood Flow Metab. 2010 Apr;30(4):883-94. doi: 10.1038/jcbfm.2009.263. Epub 2009 Dec 23.</citation>
    <PMID>20029449</PMID>
  </reference>
  <reference>
    <citation>Bouzat P, Magistretti PJ, Oddo M. Hypertonic lactate and the injured brain: facts and the potential for positive clinical implications. Intensive Care Med. 2014 Jun;40(6):920-1. doi: 10.1007/s00134-014-3312-x. Epub 2014 May 1.</citation>
    <PMID>24789621</PMID>
  </reference>
  <reference>
    <citation>Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, Bloch J, Messerer M, Levivier M, Meuli R, Magistretti PJ, Oddo M. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. 2014 Mar;40(3):412-21. doi: 10.1007/s00134-013-3203-6. Epub 2014 Jan 30.</citation>
    <PMID>24477453</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Paul Vespa, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>brain trauma, metabolic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All PHI will be expunged from records before any sharing occurs</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

